ECCO News 3/2018
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab) | Business Wire
PDF) ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology
Education
Exclusive enteral nutrition: An optimal care pathway for use in adult patients with active Crohn's disease - Day - 2020 - JGH Open - Wiley Online Library
PDF) ECCO2R therapy in the ICU: consensus of a European round table meeting
Value Chain Analysis
Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence
Review: THE TARGET by David Baldacci (Macmillan/Grand Central) | Civilian Reader
Plus Therapeutics, Inc. Free Writing Prospectus FWP
Expect more? Empty shelves frustrate Target customers, execs | MPR News
Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers - ScienceDirect
PDF) ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? | SpringerLink
PDF) Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
TARGET-IBD Poster & Oral Presentation at ECCO
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis - Allen - 2017 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
TARGET-IBD Poster & Oral Presentation at ECCO
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study | Pharmacogenomics
ECCO
PPT - A Report from ECCO 14 Oral Chemotherapy in Colorectal Cancer PowerPoint Presentation - ID:3575065
ECCO Portal
Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission | Frontline Gastroenterology
